RU2019120956A - Способы лечения воспалительных состояний легких - Google Patents

Способы лечения воспалительных состояний легких Download PDF

Info

Publication number
RU2019120956A
RU2019120956A RU2019120956A RU2019120956A RU2019120956A RU 2019120956 A RU2019120956 A RU 2019120956A RU 2019120956 A RU2019120956 A RU 2019120956A RU 2019120956 A RU2019120956 A RU 2019120956A RU 2019120956 A RU2019120956 A RU 2019120956A
Authority
RU
Russia
Prior art keywords
defensin
asthma
day
subject
peptide
Prior art date
Application number
RU2019120956A
Other languages
English (en)
Russian (ru)
Other versions
RU2019120956A3 (cg-RX-API-DMAC7.html
Inventor
Питер НОРДКИЛД
Сёрен КЬЕРУЛЬФ
Original Assignee
Дефенсин Терапьютикс Апс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дефенсин Терапьютикс Апс filed Critical Дефенсин Терапьютикс Апс
Publication of RU2019120956A publication Critical patent/RU2019120956A/ru
Publication of RU2019120956A3 publication Critical patent/RU2019120956A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2019120956A 2016-12-13 2017-12-13 Способы лечения воспалительных состояний легких RU2019120956A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201670991 2016-12-13
DKPA201670991 2016-12-13
PCT/EP2017/082535 WO2018108971A2 (en) 2016-12-13 2017-12-13 Methods for treating inflammatory conditions of the lungs

Publications (2)

Publication Number Publication Date
RU2019120956A true RU2019120956A (ru) 2021-01-15
RU2019120956A3 RU2019120956A3 (cg-RX-API-DMAC7.html) 2021-04-13

Family

ID=61024712

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019120956A RU2019120956A (ru) 2016-12-13 2017-12-13 Способы лечения воспалительных состояний легких

Country Status (13)

Country Link
US (2) US11413328B2 (cg-RX-API-DMAC7.html)
EP (1) EP3554532B1 (cg-RX-API-DMAC7.html)
JP (2) JP2020512287A (cg-RX-API-DMAC7.html)
KR (1) KR20190108106A (cg-RX-API-DMAC7.html)
CN (1) CN110290799A (cg-RX-API-DMAC7.html)
AU (1) AU2017376400A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019011844A2 (cg-RX-API-DMAC7.html)
CA (1) CA3045079A1 (cg-RX-API-DMAC7.html)
ES (1) ES2994381T3 (cg-RX-API-DMAC7.html)
MX (1) MX2019006848A (cg-RX-API-DMAC7.html)
RU (1) RU2019120956A (cg-RX-API-DMAC7.html)
SG (1) SG10202012106WA (cg-RX-API-DMAC7.html)
WO (1) WO2018108971A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200095472A (ko) * 2017-11-10 2020-08-10 디펜신 테라퓨틱스 에이피에스 조산아에서의 점막 방어 및 장/폐 기능의 성숙화
CN108815199B (zh) * 2018-08-03 2021-10-01 南华大学 鼠衣原体在制备抗溃疡性结肠炎药物中的应用
US11331269B2 (en) * 2018-09-06 2022-05-17 Massachusetts Institute Of Technology Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment
KR102742007B1 (ko) 2018-10-09 2024-12-12 유니버시티 오브 서던 캘리포니아 양이온성 마크로사이클릭 펩티드의 전신 전달성, 내약성, 및 효능을 향상시키기 위한 조성물 및 방법(compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides)
JP7479381B2 (ja) * 2019-01-07 2024-05-08 アエスクルス バイオ エーピーエス 治療または予防に使用するためのディフェンシン断片
WO2020182970A1 (en) * 2019-03-14 2020-09-17 Om Pharma Sa Process for making stable bacterial extracts and their use as pharmaceuticals
US12472231B2 (en) 2020-03-18 2025-11-18 The University Of Hong Kong Compositions of anti-viral peptides and methods of use thereof
CN113262297A (zh) * 2020-11-02 2021-08-17 中南大学湘雅二医院 一种基于巴氏菌的治疗性肺癌疫苗及其配置方法和应用
CN113521047B (zh) * 2021-08-23 2022-10-04 新疆医科大学第四附属医院 丁酸盐在制备慢性阻塞性肺疾病药物中的应用
EP4457237A4 (en) * 2021-12-27 2025-11-12 Versitech Ltd ANTIVIRAL PEPTIDES AND THEIR METHODS OF USE
CN121360148B (zh) * 2025-12-18 2026-06-30 白山市林源春生态科技股份有限公司 一种经特定发酵获得的太岁分子生态液提取物及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
CA2841097A1 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
US7511015B2 (en) * 2002-02-19 2009-03-31 The United States Of America As Represented By The Department Of Health And Human Services Modified defensins and their use
US20040091498A1 (en) 2002-05-31 2004-05-13 Aaron Diamond Aids Research Center Defensins: use as antiviral agents
GB0521139D0 (en) * 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US7528107B2 (en) 2005-11-30 2009-05-05 Auburn University Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins
WO2008115390A2 (en) 2007-03-16 2008-09-25 The Hamner Institutes For Health Sciences Methods of using defensins to treat diabetes
LT2237799T (lt) 2008-02-01 2019-07-25 Ascendis Pharma A/S Provaistas, apimantis besiskaidantį linkerį
CN102159233A (zh) 2008-07-18 2011-08-17 诺维信阿德宁生物技术公司 使用哺乳动物β防御素的炎性肠病的治疗
MX2011000569A (es) * 2008-07-18 2011-02-23 Novozymes Adenium Biotech As Tratamiento de enfermedades inflamatorias con beta-defensinas de mamifero.
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
US8828380B2 (en) * 2009-09-10 2014-09-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for the treatment of pulmonary disease and method of producing proteins of use therein
US8410049B2 (en) 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
KR101320472B1 (ko) * 2010-06-16 2013-10-23 주식회사 나이벡 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물
WO2012064601A1 (en) * 2010-11-08 2012-05-18 Pulmatrix, Inc. Methods of treating and preventing rhinovirus infection
JP6219277B2 (ja) 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブDefensin Therapeutics Aps 炎症性腸疾患の経口治療
WO2013026794A1 (en) * 2011-08-19 2013-02-28 Novozymes Novel immunomodulatory peptide
US9464124B2 (en) * 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2928910B1 (en) * 2012-12-06 2019-09-04 PIN Pharma, Inc. Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides
KR20200095472A (ko) * 2017-11-10 2020-08-10 디펜신 테라퓨틱스 에이피에스 조산아에서의 점막 방어 및 장/폐 기능의 성숙화

Also Published As

Publication number Publication date
JP2020512287A (ja) 2020-04-23
US20230067261A1 (en) 2023-03-02
US20190336576A1 (en) 2019-11-07
EP3554532B1 (en) 2024-09-25
CA3045079A1 (en) 2018-06-21
AU2017376400A1 (en) 2019-06-20
WO2018108971A3 (en) 2018-07-26
EP3554532A2 (en) 2019-10-23
BR112019011844A2 (pt) 2022-05-10
CN110290799A (zh) 2019-09-27
KR20190108106A (ko) 2019-09-23
ES2994381T3 (en) 2025-01-23
MX2019006848A (es) 2019-10-07
JP2025013922A (ja) 2025-01-28
SG10202012106WA (en) 2021-01-28
RU2019120956A3 (cg-RX-API-DMAC7.html) 2021-04-13
US11413328B2 (en) 2022-08-16
WO2018108971A2 (en) 2018-06-21
EP3554532C0 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
US20080167230A1 (en) Methods and compositions for treating or preventing lesions of the respiratory epithelium
Goh et al. Receptor-interacting protein 2 gene silencing attenuates allergic airway inflammation
US20090227511A1 (en) Methods and compositions for treating lesions of the respiratory epithelium
EP3554532B1 (en) Hbd2 for use in the treatment of inflammatory conditions of the lungs
US9833495B2 (en) Oral treatment of inflammatory bowel disease
EP2421901A2 (en) Compositions containing hc ha complex and methods of use thereof
CN102481284A (zh) 穿心莲内酯化合物用于治疗炎症和气道病症的用途
WO2019048660A1 (en) MIC-1 AND GLP-1 FOR USE IN THE TREATMENT OF OBESITY
JP2021502363A5 (cg-RX-API-DMAC7.html)
US11453880B2 (en) Chimeric decoy
EP4511004A1 (en) Inhalable pharmaceutical composition comprising the protein anakinra for the treatment of inflammation in cystic fibrosis
Ye et al. Pulmonary C-fiber degeneration downregulates IFN-γ receptor 1 via IFN-α induction to attenuate RSV-induced airway hyperresponsiveness
JP2021504348A5 (cg-RX-API-DMAC7.html)
CN117209612A (zh) 融合蛋白及其应用
CN101437849B (zh) 胰岛素衍生物
US8455437B2 (en) Method to predict and prevent oxygen-induced inflammatory tissue injury
US20240325383A1 (en) Small Molecule Targeting of BRD4 for Treatment of COVID-19
Nishimoto et al. Targeting TNF-α signaling pathway with ligand-specific antibody reverses corticosteroid insensitivity and/or airway inflammation in mice
US20120269882A1 (en) Brain Delivery of Insulin to Treat Systemic Inflammation
Li et al. Advances in the Application of Natural Compounds in Post-Lung Transplantation Management
WO2024077042A2 (en) Il-1 receptor antagonist treatment for neutrophilic lung disease
Alenzi et al. The role of eosinophils in asthma
WO2009091645A2 (en) Compositions and methods for treating chondrosarcomas
YAN et al. Clinical study on efficacy of roxithromycin combined with inhaled budesonide dry powder inhalation on asthma
Rymut et al. C60 ALL ABOUT CYSTIC FIBROSIS: High-Dose Ibuprofen Dampens Inflammatory Signaling Via Microtubule Structure And Dynamics In Cystic Fibrosis Epithelial Cells